TGF-α equalizes age disparities in stem cell-mediated cardioprotection.

Area of Science:

• Cardiovascular Research
• Stem Cell Biology
• Regenerative Medicine

Background:

• Neonatal mesenchymal stem cells (MSCs) show diminished cardioprotective potential compared to adult MSCs.
• Transforming growth factor-alpha (TGF-α) is known to boost VEGF production in adult stem cells.
• The effect of TGF-α on neonatal stem cell paracrine function and cardioprotection remains uncharacterized.

Purpose of the Study:

• To investigate if TGF-α can enhance neonatal MSCs' paracrine function and cardioprotective capabilities.
• To determine if TGF-α equalizes the paracrine function and cardioprotection between adult and neonatal MSCs.
• To assess the impact of TGF-α on stem cell-mediated recovery during acute myocardial ischemia/reperfusion.

Main Methods:

• Bone marrow MSCs from adult and neonatal mice were cultured and treated with TGF-α.
• In vitro analysis of VEGF, HGF, IGF-1, IL-1β, and IL-6 production.
• Intracoronary infusion of MSCs in an isolated heart perfusion model of ischemia/reperfusion.

Main Results:

• TGF-α treatment normalized VEGF production in both adult and neonatal MSCs, but did not alter other factors (HGF, IGF-1, IL-1β, IL-6).
• TGF-α induced greater phosphorylation of ERK, p38 MAPK, and JNK in adult MSCs.
• While adult MSCs alone improved function, TGF-α-pretreated adult and neonatal MSCs demonstrated the most significant myocardial functional recovery post-ischemia/reperfusion.

Conclusions:

• TGF-α effectively equalizes VEGF production between adult and neonatal MSCs.
• TGF-α pretreatment enhances MSC cardioprotection, leading to superior functional recovery during ischemia/reperfusion.
• Differential regulation of MAPK signaling pathways (ERK, p38, JNK) underlies TGF-α's effects on MSCs.